JP2022516557A5 - - Google Patents
Info
- Publication number
- JP2022516557A5 JP2022516557A5 JP2021538982A JP2021538982A JP2022516557A5 JP 2022516557 A5 JP2022516557 A5 JP 2022516557A5 JP 2021538982 A JP2021538982 A JP 2021538982A JP 2021538982 A JP2021538982 A JP 2021538982A JP 2022516557 A5 JP2022516557 A5 JP 2022516557A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185692A JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789075P | 2019-01-07 | 2019-01-07 | |
| US62/789,075 | 2019-01-07 | ||
| PCT/US2020/012296 WO2020146221A1 (en) | 2019-01-07 | 2020-01-06 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185692A Division JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022516557A JP2022516557A (ja) | 2022-02-28 |
| JPWO2020146221A5 JPWO2020146221A5 (https=) | 2023-01-19 |
| JP2022516557A5 true JP2022516557A5 (https=) | 2023-01-19 |
| JP7594161B2 JP7594161B2 (ja) | 2024-12-04 |
Family
ID=69374426
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538982A Active JP7594161B2 (ja) | 2019-01-07 | 2020-01-06 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
| JP2024185692A Pending JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185692A Pending JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220089667A1 (https=) |
| EP (1) | EP3908596A1 (https=) |
| JP (2) | JP7594161B2 (https=) |
| KR (1) | KR20210113265A (https=) |
| CN (1) | CN113924311A (https=) |
| AR (1) | AR117770A1 (https=) |
| AU (2) | AU2020206672B2 (https=) |
| BR (1) | BR112021012294A2 (https=) |
| CA (1) | CA3125529A1 (https=) |
| CL (1) | CL2021001779A1 (https=) |
| IL (1) | IL284633A (https=) |
| MX (1) | MX2021008147A (https=) |
| SG (1) | SG11202106700WA (https=) |
| TW (1) | TWI874345B (https=) |
| WO (1) | WO2020146221A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019028419A1 (en) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| ES3059360T3 (en) | 2018-11-08 | 2026-03-19 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| KR20260039812A (ko) | 2019-02-06 | 2026-03-20 | 신톡스, 인크. | Il-2 콘쥬게이트 및 이의 사용 방법 |
| CN114555632A (zh) | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| MX2022002740A (es) | 2019-09-10 | 2022-03-25 | Synthorx Inc | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. |
| KR102313505B1 (ko) * | 2020-06-30 | 2021-10-18 | (주)지아이이노베이션 | 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| TW202216745A (zh) * | 2020-07-02 | 2022-05-01 | 美商英伊布里克斯公司 | 包含經修飾ｉｌ－２多肽之多肽及其用途 |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| US20220144956A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| CN116829194A (zh) * | 2020-12-09 | 2023-09-29 | 亚设生物治疗公司 | 用于工程化细胞疗法的靶向细胞因子构建体 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| EP4314033A4 (en) * | 2021-03-31 | 2025-04-23 | Anwita Biosciences, Inc. | FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| WO2023004304A1 (en) * | 2021-07-20 | 2023-01-26 | Inhibrx, Inc. | Cd8-binding polypeptides and uses thereof |
| EP4395895A1 (en) * | 2021-08-30 | 2024-07-10 | Inhibrx, Inc. | Nkp46-binding polypeptides and uses thereof |
| US20240376198A1 (en) * | 2021-08-30 | 2024-11-14 | Inhibrx, Inc. | NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof |
| JP2024536840A (ja) * | 2021-09-26 | 2024-10-08 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－２バリアント及びその融合タンパク質 |
| US20250109203A1 (en) * | 2022-01-05 | 2025-04-03 | Inhibrx Biosciences, Inc. | Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof |
| EP4561632A2 (en) * | 2022-07-28 | 2025-06-04 | Proviva Therapeutics (Hong Kong) Limited | Il-2 procytokine antibody fusion proteins |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1678314E (pt) | 2003-10-22 | 2012-11-27 | Keck Graduate Inst | Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| BRPI0508470A (pt) * | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EP3795215A1 (en) * | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| KR102042246B1 (ko) * | 2014-02-06 | 2019-11-28 | 에프. 호프만-라 로슈 아게 | 인터류킨-2 융합 단백질 및 이의 용도 |
| WO2017121758A1 (en) * | 2016-01-11 | 2017-07-20 | Universität Zürich | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent |
| KR102687530B1 (ko) * | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| IL269000B2 (en) * | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| TWI690538B (zh) * | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
| JP2020521452A (ja) * | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2020
- 2020-01-06 KR KR1020217024431A patent/KR20210113265A/ko active Pending
- 2020-01-06 CA CA3125529A patent/CA3125529A1/en active Pending
- 2020-01-06 TW TW109100336A patent/TWI874345B/zh active
- 2020-01-06 JP JP2021538982A patent/JP7594161B2/ja active Active
- 2020-01-06 CN CN202080018011.6A patent/CN113924311A/zh active Pending
- 2020-01-06 EP EP20702547.9A patent/EP3908596A1/en active Pending
- 2020-01-06 MX MX2021008147A patent/MX2021008147A/es unknown
- 2020-01-06 US US17/418,458 patent/US20220089667A1/en active Pending
- 2020-01-06 SG SG11202106700WA patent/SG11202106700WA/en unknown
- 2020-01-06 AR ARP200100028A patent/AR117770A1/es unknown
- 2020-01-06 AU AU2020206672A patent/AU2020206672B2/en active Active
- 2020-01-06 WO PCT/US2020/012296 patent/WO2020146221A1/en not_active Ceased
- 2020-01-06 BR BR112021012294-0A patent/BR112021012294A2/pt unknown
-
2021
- 2021-07-05 CL CL2021001779A patent/CL2021001779A1/es unknown
- 2021-07-05 IL IL284633A patent/IL284633A/en unknown
-
2024
- 2024-10-22 JP JP2024185692A patent/JP2025013911A/ja active Pending
-
2025
- 2025-12-19 AU AU2025283608A patent/AU2025283608A1/en active Pending